ABSTRACT
Objective To assess saliva as a substrate to measure CGRP by comparing interictal levels of CGRP in patients with episodic migraine and controls; and to evaluate saliva CGRP temporal profile during migraine attacks.
Methods This prospective observational study included women with episodic migraine and healthy controls. Participants collected daily saliva samples for 30 consecutive days and 3 additional ones during migraine attacks. 4 timepoints were considered: interictal (72h headache-free), preictal (PRE-24h before the attack), ictal (0h,2h,8h), postictal (POST-24h after the attack). CGRP levels were quantified by ELISA.
Results 35 women (22 patients, 13 controls) were included. Statistically significant differences were found in interictal salivary levels of CGRP between patients and controls (median[IQR]: 98.0 [86.7] vs. 42.2 [44.7] pg/mL; p=0.010). An increase in CGRP levels during migraine attacks was detected (median[IQR]: preictal 113.5 [137.8], 0h 164.6 [204.5], 2h 101.7 [159.1], 8h 82.6 [166.2], postictal 79.6 [124.3] pg/ml; p<0.001). Patients were classified as having CGRP-dependent (80.0%) and non-CGRP dependent migraine attacks (20.0%) according to the magnitude of change between preictal and ictal phase (0h). Accompanying symptoms were different depending on the type of attack. In the longitudinal analysis, we observed that the amount of CGRP measured during attacks were phase dependent and it was influenced by the frequency of monthly headache days (p=0.02).
Interpretation Patients with episodic migraine have higher interictal salivary levels of CGRP than controls. These levels usually increase during a migraine attack, however, not every attack is CGRP-dependent, which in turn, might explain different underline pathophysiology and response to acute and preventive treatment.
Competing Interest Statement
In relation with this paper, the authors have no conflicts of interest. Alpuente A has received honoraria as speaker for Allergan and for education from Novartis and Chiesi. Gallardo VJ, Asskour L and Caronna E have nothing to disclose. Torres-Ferrus M has received honoraria as a speaker for Allergan, Chiesi, Eli Lilly and Novartis. Pozo-Rosich P has received honoraria as a consultant and speaker for Allergan, Almirall, Biohaven, Chiesi, Eli Lilly, Medscape, Neurodiem, Novartis and Teva Pharmaceuticals. Her research group has received research grants from Allergan, AGAUR, la Caixa foundation, Migraine Research Foundation, Instituto de Salud Carlos III, MICINN, Novartis, PERIS; and has received funding for clinical trials from Alder, Electrocore, Eli Lilly, Novartis and Teva. She is a trustee member of the board of the International Headache Society and a member of the Council of the European Headache Federation. She is in the editorial board of Revista de Neurologia. She is an associate editor for Cephalalgia, Frontiers of Neurology, Headache and Neurologia; and, the advisory board of the Journal of Headache and Pain. She is a member of the Clinical Trials Guidelines Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of www.midolordecabeza.org. She does not own stocks from any pharmaceutical company.
Funding Statement
This study was funded by a grant from Instituto de Salud Carlos III (ISCIII - PI16/01525) and Alicia Alpuente has been partially financed by a grant from the Headache Study Group of the Spanish Neurological Society 2018.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
AA, VJG, MTF and PPR made substantial contributions to the conception and design of the study. LA made substantial contribution to the methodology and she performed the ELISA protocol. AA wrote first draft of the paper. VJG performed statistical analysis. All authors participated in acquisition, analysis and/or interpretation of data. All authors have critically revised and finally approved the version to be published
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
